Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms P95HER2-T cell bispecific antibody (Roche) |
Target |
Action inhibitors |
Mechanism p95HER2 inhibitors(HER2-p95 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | Spain | 03 Oct 2018 | |
Breast Cancer | Preclinical | Switzerland | 03 Oct 2018 |